Shelley Hall, MD
Advanced Heart Failure and Transplant Cardiology · Dallas, TXNPI 1912961145
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $157,730 of the $253,895 with a category attached, or 62.1%. 21 manufacturers reported payments, led by Abbott at 50.6% of the total. 2025 is the largest year on record at $92,741, 3.1 times the $29,826 reported in 2019. Among advanced heart failure and transplant cardiology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 372 payments — averaging $682.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$128K
- Cvrx, Inc.$49K
- Abiomed$32K
- Novartis$25K
- Medtronic$11K
- Sanofi-aventis U.S. LLC$7K
- plus $1K from 15 others
Across 166 payments — averaging $6385.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$703K
- Novartis$183K
- American Regent$70K
- Veloxis Pharmaceuticals, Inc.$59K
- Actelion Pharmaceuticals, Ltd$30K
- Sanofi US Services Inc.$16K
What the payments were for
- Consulting fees$157,73062%
- Speaking & faculty fees$57,83123%
- Grants$7500%
- Travel & lodging$22,9329%
- Food & beverage$14,6536%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 218 | $128,495 |
| Cvrx, Inc. | 61 | $49,353 |
| Abiomed | 24 | $32,164 |
| Novartis | 28 | $24,769 |
| Medtronic(2 entities) | 18 | $11,051 |
| Sanofi-aventis U.S. LLC | 2 | $6,709 |
| Heartflow, Inc. | 1 | $350 |
| Atricure, Inc. | 2 | $201 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $184 |
| Alnylam Pharmaceuticals Inc. | 3 | $150 |
| Ancora Heart, Inc. | 1 | $132 |
| ZOLL Respicardia, Inc. | 2 | $101 |
| Merck | 2 | $97 |
| Amgen | 1 | $22 |
| Briohealth Solutions, Inc. | 1 | $20 |
| Nuwellis, Inc. | 1 | $20 |
| W. L. Gore & Associates, Inc. | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$69,584
- Barostim Neo System$48,032
- Impella$31,812
- ENTRESTO$24,436
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$22,789
- HeartMate 3 Left Ventricular Dev$18,949
- HeartWare HVAD$9,506
- THYMOGLOBULIN$5,959
- CardioMEMS HF System$5,386
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$4,329
- HeartMate 3 Left Ventricular Assist Device$4,195
- HeartMate$541
- FFRct$350
- AccuCinch$132
- THORATEC HEARTMATE II, LVAS IMPLANT KIT$131
- ATRICURE CRYOSURGICAL SYSTEM$121
- ATRICURE SYNERGY ABLATION SYSTEM$121
How this compares
$253,895 in reported general payments places this provider in the 90th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
See all advanced heart failure and transplant cardiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 32 | $39,471 |
| EliquisApixaban | 12 | $18,673 |
| Sirolimus | 39 | $8,995 |
| Cyclosporine ModifiedCyclosporine, Modified | 21 | $8,224 |
| Tacrolimus | 77 | $5,170 |
| Mycophenolate Mofetil | 36 | $2,424 |
| Torsemide | 23 | $530 |
| Ezetimibe | 28 | $500 |
| Rosuvastatin Calcium | 35 | $484 |
| Fluconazole | 12 | $405 |
| Metoprolol Succinate | 21 | $397 |
| Spironolactone | 33 | $347 |
| Atorvastatin Calcium | 36 | $338 |
| Prednisone | 35 | $312 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 48 | $282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $24,769 | $39,47132 claims |
| PfizerEliquis | $16 | $18,67312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
Other advanced heart failure and transplant cardiology in Dallas
- Robert GottliebDallas$717K
- Martin BerkDallas$379K
- Maryjane FarrDallas$148K
- Claudius MahrDallas$87K
- Kartik TelukuntlaDallas$80K
- Song LiDallas$27K
- Farah Al-SaffarDallas$24K
- Srikant PatlollaDallas$23K
- Nicholas HendrenDallas$12K
- Brian HsiDallas$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.